Autologous Matrix-induced Chondrogenesis Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Collagen Membrane, Hyaluronic Acid Scaffold, Synthetic Polymers, Others), By Application (Knee, Hip, Ankle, Elbow, Shoulder, Others), By End User (Hospitals, Orthopedic Clinics, Ambulatory Surgery Centers, Specialized Regenerative Medicine Centers, Others) and Region Forecast 2020-2031

Autologous Matrix-induced Chondrogenesis Market size was valued at US$ 200.3 million in 2024 and is projected to reach US$ 347.8 million by 2031 at a CAGR of 8.1% form 2025-2031. Moreover, the U.S. Autologous Matrix-induced Chondrogenesis Market is projected to grow at a CAGR of 8.2% over forecast period.

Autologous Matrix-Induced Chondrogenesis (AMIC) refers to a single-step cartilage repair technique combining microfracture surgery with an application of a biocompatible matrix (often a collagen or other scaffold membrane) over the defect. The microfracture allows bone marrow-derived cells (mesenchymal stem cells etc.) to enter the defect site, and the matrix helps guide their differentiation and protect the repair environment, aiming to regenerate articular cartilage.

AMIC is used to treat chondral and osteochondral lesions (in joints such as knee, hip, ankle, elbow, etc.), with the goal of reducing pain, restoring joint function, slowing down cartilage degeneration, and delaying or avoiding more invasive procedures like partial or total joint replacement.

Key Developments

• In March 2025, Geistlich Pharma introduced an enhanced version of its Chondro-Gide® collagen membrane, designed to improve integration and support for cartilage regeneration in knee and hip joints. The updated membrane features advanced biomaterial properties aimed at optimizing healing outcomes.
• In July 2025, A clinical study published in ScienceDirect reported that patients undergoing AMIC procedures with collagen-based scaffolds exhibited promising recovery trajectories. The study highlighted the potential of collagen membranes in facilitating cartilage repair, though it noted the need for further data beyond 36 months to fully assess long-term efficacy.

Autologous Matrix Induced Chondrogenesis Market Segmentation

Based on the product type

• Collagen Membrane
• Hyaluronic Acid Scaffold
• Synthetic Polymers
• Others

Among the various factors driving the growth of the market, the increasing adoption of collagen membrane-based products stands out as the leading driver. Collagen membranes are highly favored due to their excellent biocompatibility, structural support, and ability to facilitate cell attachment and proliferation, making them ideal for cartilage regeneration. The preference for collagen membranes is reinforced by their proven clinical effectiveness in repairing articular cartilage defects, particularly in the knee joint. As a result, healthcare providers and patients increasingly choose collagen-based AMIC procedures, positioning this segment as a primary catalyst for overall market expansion.

Based on the application

• Knee
• Hip
• Ankle
• Elbow
• Shoulder
• Others

Among the various applications of AMIC, the knee segment is the leading contributor to market growth. The knee joint is particularly prone to cartilage injuries due to sports activities, aging, and lifestyle-related wear and tear, which has created significant demand for effective cartilage repair solutions. AMIC procedures targeting the knee are highly preferred because they offer minimally invasive treatment, faster recovery, and improved joint functionality. The established clinical success of knee cartilage repair with AMIC has encouraged widespread adoption among orthopedic surgeons and patients, positioning the knee application segment as the primary driver of overall market expansion.

Based on the end user

• Hospitals
• Orthopedic Clinics
• Ambulatory Surgery Centers
• Specialized Regenerative Medicine Centers
• Others

Among the end-user segments, hospitals are the primary drivers of growth in the market. Hospitals provide comprehensive infrastructure, advanced surgical facilities, and access to highly skilled orthopedic surgeons, making them the preferred setting for performing AMIC procedures. Their capability to handle complex cases and offer post-operative care ensures better patient outcomes, which increases trust and adoption of AMIC treatments. Furthermore, hospitals often lead in introducing new technologies and regenerative medicine solutions, creating a favorable environment for market expansion. As a result, hospitals remain the dominant end-user segment, significantly influencing the overall growth trajectory of the AMIC market.